XT
Adastra Holdings Ltd.
XTXXF · OTC
$0.01 +0.00% (+$0.00)
Market Cap $55.7K
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.01
42.9% upside
Current Price
$0.007
Undervalued Fair Value Overvalued
According to Bulios Fair Price, XTXXF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/FCF 5.33x
P/S 0.00x
EV/FFO N/A
Growth
78 /100
Growing Book val. growth 59.83%
Rev. growth 64.03%
FCF growth N/A
Profitability
15 /100
Weak Op. margin 14.42%
Gross margin 33.19%
FCF margin 0.06%
Quality
19 /100
Poor Asset turnover 1.05x
ROIC 89.02%
ROA 89.41%
Debt
0 /100
High Int. coverage -12.70x
Current ratio 0.38x
Debt/Assets N/A
Stability
13 /100
Unstable EPS volatility 2,089.28%
Beta -0.51x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about XTXXF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Brian O'Neill
Employees
21
Headquarters
Langley
Upcoming events
26 NOV
Earnings
Upcoming earnings report